6 products found
Zymeworks Inc Products
-
Pipeline
-
Zanidatamab - Bispecific Antibody
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other tumor ...
-
Zymeworks - Model ZW49 - Bispecific Antibody Drug Conjugate (ADC)
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted agents. ZW49 combines the unique design of zanidatamab with a ...
-
Technology
-
Azymetric - Tailored Multifunctional Therapeutics
by creating tailored multifunctional therapeutics that enable enhanced efficacy and new biological approaches for treating diseases. Two is better than one. Create novel mechanisms of action through unique binding. Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical ...
-
Zymelink - Enhance Therapeutic Response Cell
with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. A broader window of opportunity. Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. ...
-
Zymeworks - Model EFECT - Customize & Optimize Immune Response Cell
using precise antibody Fc modifications that tailor the antibody-mediated immune response. Get the optimal response. Tailor immune system response for a desired therapeutic effect using the Effector Function Enhancement and Control Technology’s (EFECT™) library of Fc region modifications. The EFECT™ library includes proprietary mutations to the CH2 domain of the antibody's Fc region to selectively modulate an antibody’s ...
-
Protect - Tumor-Specific Immune Co-Stimulation Platform
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory pair such as PD-1/PD-L1. Therapeutics utilizing ProTECT™ have limited exposure and activity in normal ...